According to filings with the U.S. Securities and Exchange Commission, Flagship Biosciences is raising up to $6,369,795.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Trevor Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Flagship Biosciences
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success.

To learn more about Flagship Biosciences, visit http://www.flagshipbio.com/

Contact:
Trevor Johnson, Chief Executive Officer
303-325-5894
https://www.linkedin.com/in/trevor-johnson-8b66716/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.